BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C, Su K, Chang Y, Wu C, Hsu C, Liao B, Hsu W, Lee J, Lin C, Shih J, Yang JC, Yu C. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. European Journal of Cancer 2020;124:110-22. [DOI: 10.1016/j.ejca.2019.10.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu QX, Wei JG, Chen YY, Wang JF. Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report. Medicine (Baltimore) 2022;101:e30099. [PMID: 35984168 DOI: 10.1097/MD.0000000000030099] [Reference Citation Analysis]
2 Teranishi S, Sugimoto C, Nagaoka S, Nagayama H, Segawa W, Miyasaka A, Hiro S, Kajita Y, Maeda C, Kobayashi N, Yamamoto M, Kudo M, Kaneko T. Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib. Thoracic Cancer. [DOI: 10.1111/1759-7714.14608] [Reference Citation Analysis]
3 Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Huang YH, Chang GC. PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep 2022;12:9753. [PMID: 35697720 DOI: 10.1038/s41598-022-13102-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bahnassy AA, Ismail H, Mohanad M, El-bastawisy A, Yousef HF. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt. J Egypt Natl Canc Inst 2022;34. [DOI: 10.1186/s43046-022-00121-8] [Reference Citation Analysis]
5 Zhou Y, Song L, Xu Q, Zeng L, Jiang W, Yang N, Zhang Y. Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib. Lung Cancer 2022;167:58-64. [PMID: 35405360 DOI: 10.1016/j.lungcan.2022.04.002] [Reference Citation Analysis]
6 Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, Yang X. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC. Future Oncol 2022. [PMID: 35232247 DOI: 10.2217/fon-2021-0862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yang X, Jiang L, Jin Y, Li P, Hou Y, Yun J, Wu C, Sun W, Fan X, Kuang D, Wang W, Ni J, Mao A, Tang W, Liu Z, Wang J, Xiao S, Li Y, Lin D. PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. J Cancer 2021;12:7390-8. [PMID: 35003359 DOI: 10.7150/jca.63003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Li M, Hou X, Chen J, Zhang B, Wang N, Han H, Chen L. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tian T, Yu M, Li J, Jiang M, Ma D, Tang S, Lin Z, Chen L, Gong Y, Zhu J, Zhou Q, Huang M, Lu Y. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. Front Oncol 2021;11:739090. [PMID: 34888234 DOI: 10.3389/fonc.2021.739090] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
10 Tsubata Y, Tanino R, Isobe T. Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. Cells 2021;10:3192. [PMID: 34831415 DOI: 10.3390/cells10113192] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer 2021;159:144-53. [PMID: 34749119 DOI: 10.1016/j.ejca.2021.09.041] [Reference Citation Analysis]
12 Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Nishiyama A, Yano S, Goto Y, Shiotsu S, Kunimasa K, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Kenmotsu H, Takahashi T, Takayama K. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res 2021;10:3582-93. [PMID: 34584858 DOI: 10.21037/tlcr-21-461] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Lan B, Wang Y, Wu J, Wang K, Wang P. The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis. Medicine (Baltimore) 2021;100:e27038. [PMID: 34449486 DOI: 10.1097/MD.0000000000027038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Xiao G, Liu Z, Gao X, Wang H, Peng H, Li J, Yang L, Duan H, Zhou R. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. Immunotherapy 2021;13:1031-51. [PMID: 34231370 DOI: 10.2217/imt-2020-0262] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Bironzo P, Reale ML, Sperone T, Tabbò F, Caglio A, Listì A, Passiglia F, Di Maio M, Righi L, Bussolino F, Scagliotti GV, Novello S. Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. Cancers (Basel) 2021;13:2425. [PMID: 34067823 DOI: 10.3390/cancers13102425] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 He Q, Li Y, Zhou X, Zhou W, Xia C, Zhang R, Zhang Z, Hu A, Peng S, Li J. The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs. J Int Med Res 2021;49:3000605211004021. [PMID: 33794676 DOI: 10.1177/03000605211004021] [Reference Citation Analysis]
17 Peng Z, Lin H, Zhou K, Deng S, Mei J. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J Surg Oncol 2021;19:145. [PMID: 33964931 DOI: 10.1186/s12957-021-02254-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
18 Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K, Han R, Qiao M, Li W, Yu J, Zhou F, Xiong A, Chen B, Fan J, Ren S, Zhou C. Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Front Oncol 2021;11:639947. [PMID: 33777802 DOI: 10.3389/fonc.2021.639947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 Liu J, Itchins M, Nagrial A, Cooper WA, De Silva M, Barnet M, Varikatt W, Sivasubramaniam V, Davis A, Gill AJ, Blinman P, Lee K, Hui R, Gao B, Pavlakis N, Clarke S, Lee J, Boyer M, Kao S. Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2021;155:28-33. [PMID: 33721613 DOI: 10.1016/j.lungcan.2021.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Chen CJ, Liu YP. MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2021;14:130. [PMID: 33562150 DOI: 10.3390/ph14020130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Leng X, Wei S, Mei J, Deng S, Yang Z, Liu Z, Guo C, Deng Y, Xia L, Cheng J, Zhao K, Gan F, Li C, Merrell KW, Molina JR, Metro G, Liu L. Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. Transl Lung Cancer Res 2021;10:965-80. [PMID: 33718036 DOI: 10.21037/tlcr-21-146] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Kang M, Park C, Kim SH, Yoon SW, Suh KJ, Kim YJ, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Transl Lung Cancer Res 2021;10:699-711. [PMID: 33718015 DOI: 10.21037/tlcr-20-893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhou J, Yu X, Hou L, Zhao J, Zhou F, Chu X, Wu Y, Zhou C, Su C. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer. Lung Cancer 2021;153:143-9. [PMID: 33508527 DOI: 10.1016/j.lungcan.2021.01.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, Zhang S, Jing W, Ma J, Han C. Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review. Front Oncol 2020;10:610923. [PMID: 33363040 DOI: 10.3389/fonc.2020.610923] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
25 Chang GC, Yang TY, Chen KC, Hsu KH, Huang YH, Su KY, Yu SL, Tseng JS. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci Rep 2020;10:21063. [PMID: 33273548 DOI: 10.1038/s41598-020-78152-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
26 Xu JL, Wang XZ, Jiang HN, Chen Y, Wang R, Shu YQ. Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer. Chin Med J (Engl) 2020;133:2495-7. [PMID: 32941237 DOI: 10.1097/CM9.0000000000001070] [Reference Citation Analysis]
27 Li R, Liu X, Zhou XJ, Chen X, Li JP, Yin YH, Qu YQ. Identification of a Prognostic Model Based on Immune-Related Genes of Lung Squamous Cell Carcinoma. Front Oncol 2020;10:1588. [PMID: 33014809 DOI: 10.3389/fonc.2020.01588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yoon BW, Chang B, Lee SH. High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. Onco Targets Ther 2020;13:8273-85. [PMID: 32903896 DOI: 10.2147/OTT.S271011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
29 Jin D, Song Y, Chen Y, Zhang P. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma. Biomed Res Int 2020;2020:7929132. [PMID: 32596372 DOI: 10.1155/2020/7929132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
30 Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist 2020;25:702-11. [PMID: 32386255 DOI: 10.1634/theoncologist.2020-0088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]